Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
NVS vs. LLY: Which Stock Should Value Investors Buy Now?
12:41pm, Tuesday, 17'th Dec 2024
Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?
Are Investors Undervaluing Novartis (NVS) Right Now?
10:40am, Tuesday, 17'th Dec 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Novartis: Time To Increase
07:28am, Friday, 13'th Dec 2024
Novartis faces headwinds from Kisqali patent litigation and Entresto competition, but clinical advancements and increased mid-term sales guidance support our Buy rating. Key growth drivers include hig
The Zacks Analyst Blog Mastercard, The Procter & Gamble, Novartis AG, IDT and GSI Technology
03:15am, Friday, 13'th Dec 2024
Mastercard, The Procter & Gamble, Novartis AG, IDT and GSI Technology are included in this Analyst Blog.
Basel, December 10, 2024 – Novartis today announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqali® (ribociclib) that underscore the extended efficacy beyond the
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
02:21pm, Monday, 09'th Dec 2024
NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 therapies.
Basel, December 8, 2024 – Novartis today announced positive, longer-term results from the pivotal Phase III ASC4FIRST trial with Scemblix® (asciminib) showing superior major molecular response (MMR
12 High-Yield Dividend Aristocrats To Weather The Coming 2025 Storm In Style
07:00am, Saturday, 07'th Dec 2024
The S&P is up almost 28% in 2024, and many investors worry about a melt-up followed by a sharp correction like in 2022 or 2018. A 2025 market correction is likely, but low-volatility, high-yield Divid
Basel, December 6, 2024 – Novartis today announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta® (iptaco
Novartis cannot block generic of best-selling heart drug, US appeals court says
12:07pm, Wednesday, 04'th Dec 2024
Novartis failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' blockbuster heart drug Entresto.
Why Novartis (NVS) is a Top Growth Stock for the Long-Term
10:51am, Wednesday, 04'th Dec 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
02:40pm, Tuesday, 03'rd Dec 2024
NVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug.
Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide Forward
04:27pm, Monday, 02'nd Dec 2024
Olema Pharmaceuticals, Inc. entered into an agreement with Novartis to obtain KISQALI supply for the soon-to-be initiated phase 3 OPERA-02 study, targeting patients with ER+/HER2- metastatic breast ca
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
12:58pm, Monday, 02'nd Dec 2024
On Monday, PTC Therapeutics, Inc. PTCT signed an exclusive global license and collaboration agreement with Novartis AG NVS for its PTC518 Huntington's disease program, which includes related molecul
PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis
07:14am, Monday, 02'nd Dec 2024
PTC Therapeutics has entered into a licensing deal with a unit of Novartis AG for up to $1.9 billion, the company said on Monday, for its experimental drug being developed for a rare neurological diso
